Biomarkers in lung cancer screening: the importance of study design

David R Baldwin^{1

2}, Matthew E Callister^{3

4}, Philip A Crosbie^{5

6}, Emma L O'Dowd^{7

2}, Robert C Rintoul^{8

9}, Hilary A Robbins¹⁰, Robert J C Steele¹¹

Affiliations

¹ Respiratory Medicine, Nottingham University Hospitals, Nottingham, UK david.baldwin@nottingham.ac.uk.
² University of Nottingham, Nottingham, UK.
³ Leeds Teaching Hospitals, Leeds, UK.
⁴ University of Leeds, St James's University Hospital, Leeds, UK.
⁵ Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK.
⁶ Manchester Thoracic Oncology Centre, North West Lung Centre, Manchester University NHS Foundation Trust, Manchester, UK.
⁷ Respiratory Medicine, Nottingham University Hospitals, Nottingham, UK.
⁸ Dept of Oncology, University of Cambridge, Cambridge, UK.
⁹ Dept of Thoracic Oncology, Royal Papworth Hospital, Cambridge, UK.
¹⁰ Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France.
¹¹ UK National Screening Committee, Dept of Surgery, Ninewells Hospital, University of Dundee, Dundee, UK.

PMID: 33446580
PMCID: PMC7968073
DOI: 10.1183/13993003.04367-2020

Editorial

Biomarkers in lung cancer screening: the importance of study design

David R Baldwin et al. Eur Respir J. 2021.

. 2021 Jan 14;57(1):2004367.

doi: 10.1183/13993003.04367-2020. Print 2021 Jan.

Authors

David R Baldwin^{1

2}, Matthew E Callister^{3

4}, Philip A Crosbie^{5

6}, Emma L O'Dowd^{7

2}, Robert C Rintoul^{8

9}, Hilary A Robbins¹⁰, Robert J C Steele¹¹

Affiliations

¹ Respiratory Medicine, Nottingham University Hospitals, Nottingham, UK david.baldwin@nottingham.ac.uk.
² University of Nottingham, Nottingham, UK.
³ Leeds Teaching Hospitals, Leeds, UK.
⁴ University of Leeds, St James's University Hospital, Leeds, UK.
⁵ Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK.
⁶ Manchester Thoracic Oncology Centre, North West Lung Centre, Manchester University NHS Foundation Trust, Manchester, UK.
⁷ Respiratory Medicine, Nottingham University Hospitals, Nottingham, UK.
⁸ Dept of Oncology, University of Cambridge, Cambridge, UK.
⁹ Dept of Thoracic Oncology, Royal Papworth Hospital, Cambridge, UK.
¹⁰ Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France.
¹¹ UK National Screening Committee, Dept of Surgery, Ninewells Hospital, University of Dundee, Dundee, UK.

PMID: 33446580
PMCID: PMC7968073
DOI: 10.1183/13993003.04367-2020

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: D.R. Baldwin reports personal fees from AstraZeneca, MSD, BMS, Roche and Johnson and Johnson, outside the submitted work. Conflict of interest: M.E. Callister has nothing to disclose. Conflict of interest: P.A. Crosbie reports personal fees from AstraZeneca and Novartis, personal fees and other from Everest Detection, outside the submitted work. Conflict of interest: E.L. O'Dowd has nothing to disclose. Conflict of interest: R.C. Rintoul reports personal fees from AstraZeneca and Roche, outside the submitted work; and is Chief Investigator of the LuCiD study, sponsored by Owlstone Medical but declares no financial support or financial interest in Owlstone Medical. Conflict of interest: H.A. Robbins has nothing to disclose. Conflict of interest: R.J.C. Steele has nothing to disclose.

Comment on

Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging.
Sullivan FM, Mair FS, Anderson W, Armory P, Briggs A, Chew C, Dorward A, Haughney J, Hogarth F, Kendrick D, Littleford R, McConnachie A, McCowan C, McMeekin N, Patel M, Rauchhaus P, Ritchie L, Robertson C, Robertson J, Robles-Zurita J, Sarvesvaran J, Sewell H, Sproule M, Taylor T, Tello A, Treweek S, Vedhara K, Schembri S; Early Diagnosis of Lung Cancer Scotland (ECLS) Team. Sullivan FM, et al. Eur Respir J. 2021 Jan 14;57(1):2000670. doi: 10.1183/13993003.00670-2020. Print 2021 Jan. Eur Respir J. 2021. PMID: 32732334 Free PMC article. Clinical Trial.
Validation of Lung EpiCheck, a novel methylation-based blood assay, for the detection of lung cancer in European and Chinese high-risk individuals.
Gaga M, Chorostowska-Wynimko J, Horváth I, Tammemagi MC, Shitrit D, Eisenberg VH, Liang H, Stav D, Levy Faber D, Jansen M, Raviv Y, Panagoulias V, Rudzinski P, Izbicki G, Ronen O, Goldhaber A, Moalem R, Arber N, Haas I, Zhou Q. Gaga M, et al. Eur Respir J. 2021 Jan 14;57(1):2002682. doi: 10.1183/13993003.02682-2020. Print 2021 Jan. Eur Respir J. 2021. PMID: 33122336 Free PMC article.

References

1. National Lung Screening Trial Research Team, Aberle DR, Adams AM et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365: 395–409. - PMC - PubMed
1. de Koning HJ, van der Aalst CM, de Jong PA et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med 2020; 382: 503–513. - PubMed
1. Ten Haaf K, Jeon J, Tammemagi MC et al. Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study. PLoS Med 2017; 14: e1002277. - PMC - PubMed
1. Tammemagi MC, Schmidt H, Martel S et al. Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study. Lancet Oncol 2017; 18: 1523–1531. - PubMed
1. Field JK, Duffy SW, Baldwin DR et al. UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening. Thorax 2016; 71: 161–170. - PMC - PubMed

Publication types

Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Biomarkers in lung cancer screening: the importance of study design

Affiliations

Biomarkers in lung cancer screening: the importance of study design

Authors

Affiliations

Conflict of interest statement

Comment on

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical